Cargando…

Clinical effect of MUC1 and its relevance to BRAF V600E mutation in papillary thyroid carcinoma: a case–control study

AIM: To investigate the clinical effects of MUC1 on papillary thyroid cancer (PTC) and explore the relationship between MUC1 expression and BRAF mutation. METHODS: The data of 69 patients subjected to fine-needle aspiration biopsy in our hospital and 486 patient data downloaded from The Cancer Genom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Quan, Jin, Wen-Xu, Jin, Yi-Xiang, Zheng, Zhou-Ci, Zhou, Xiao-Fen, Wang, Qing-Xuan, Ye, Dan-Rong, Sun, Yi-Han, Zhang, Xiao-Hua, Wang, Ou-Chen, Chen, En-Dong, Cai, Ye-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985787/ https://www.ncbi.nlm.nih.gov/pubmed/29881305 http://dx.doi.org/10.2147/CMAR.S161501

Ejemplares similares

Predictive Factors of Skip Metastasis in Papillary Thyroid Cancer
por: Jin, Wen-Xu, et al.
Publicado: (2018)

Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma
por: Wang, Qing-Xuan, et al.
Publicado: (2016)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population
por: Ye, Ziheng, et al.
Publicado: (2022)

Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto’s Thyroiditis
por: Zhang, Qin, et al.
Publicado: (2017)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

BRAF(V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules
por: Wu, Ya, et al.
Publicado: (2019)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Prediction of central lymph node metastasis in papillary thyroid microcarcinoma according to clinicopathologic factors and thyroid nodule sonographic features: a case-control study
por: Jin, Wen-Xu, et al.
Publicado: (2018)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

High BRAF(V600E) mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules
por: Li, Xing-Jia, et al.
Publicado: (2019)

The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma: A Large Case-control Study
por: Cai, Ye-Feng, et al.
Publicado: (2015)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation
por: Liang, Songnian, et al.
Publicado: (2022)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Radiomic Model for Determining the Value of Elasticity and Grayscale Ultrasound Diagnoses for Predicting BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wang, Yu-guo, et al.
Publicado: (2022)

Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAF(V600E) Mutation and Clinicopathological Features
por: Li, Gui-you, et al.
Publicado: (2020)

DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer
por: Ma, Ben, et al.
Publicado: (2016)

Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Braf(v600e) Mutation: A Single Center Study of 1,207 Chinese Patients
por: Xue, Shuai, et al.
Publicado: (2019)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

Detection of BRAF V600E in Fine-Needle Aspiration Samples of Thyroid Nodules by Droplet Digital PCR
por: Lu, Sang-Yu, et al.
Publicado: (2022)

A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
por: Pancer, Jill, et al.
Publicado: (2019)

MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
por: Zheng, Tingting, et al.
Publicado: (2023)

Association between BRAF(V600E) mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma
por: Lu, Hai-Zhen, et al.
Publicado: (2017)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_egh7huepm0bj6qpn9bhht8oima